Vanderbilt Vaccine Research Program Archives
Study finds Moderna’s COVID-19 vaccine safe and effective for young children
Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.
VUMC study will evaluate alternative strategies for administering monkeypox vaccine
Sep. 7, 2022—Vanderbilt is seeking about 30 healthy adults of diverse backgrounds to participate in a national clinical trial to evaluate alternative strategies for administering the monkeypox vaccine
Study to evaluate nasal flu vaccine for children
Jul. 28, 2022—Pediatricians with the Vanderbilt Vaccine Research Program are looking for healthy infants and children (6 months – 8 years of age) to take part in a nasal influenza vaccine study.
VUMC-led study finds Moderna COVID vaccine safe and effective for children
May. 12, 2022— by Bill Snyder Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found. The two-dose vaccine (given approximately one month apart) led to antibody responses in more than...
MIS-C diagnosis rare in vaccinated children with no previous COVID-19 diagnosis
Feb. 24, 2022—A Vanderbiltl study found that children who received the COVID-19 vaccine who had not previously been diagnosed with COVID infection are unlikely to be diagnosed with multisystem inflammatory syndrome in children (MIS-C).
Study finds shorter treatment better for young children with outpatient pneumonia
Feb. 3, 2022—A Vanderbilt study found that five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized.
Weigh risks, plan ahead prior to gathering for the holidays
Dec. 8, 2021—Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers.
Heparin, platelets discouraged as treatment for blood clots after COVID vaccine
May. 12, 2021—Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.
Investigational vaccine to be tested against COVID-19 variant
Apr. 2, 2021—Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.
Coronavirus ‘crusaders’ spur VUMC research achievements
Dec. 16, 2020—The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.
VUMC begins study of second COVID-19 vaccine
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Remdesivir helps reduce COVID-19 recovery time: study
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
